<DOC>
	<DOCNO>NCT00058422</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab yttrium Y 90 ibritumomab tiuxetan locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining rituximab combination chemotherapy yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine rituximab combination chemotherapy yttrium Y 90 ibritumomab tiuxetan treat old patient B-cell lymphoma previously treat .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan Treating Older Patients With Previously Untreated B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free overall survival patient age 60 previously untreated diffuse large B-cell lymphoma treat rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP ) combine yttrium Y 90 ibritumomab tiuxetan . - Determine incidence adverse experience , hematologic toxicity ( WBC , hemoglobin , platelet nadir ; transfusion requirement ) , cardiac toxicity ( incidence leave ventricular dysfunction cardiomyopathy echocardiography ) , development human antimouse antibody/human anti-chimeric antibody patient treat regimen . - Determine predictive value detect minimal residual disease molecular technique future relapse/recurrence patient treat regimen . - Determine response rate patient treat regimen . - Determine red blood cell transfusion requirement , change hemoglobin baseline , incidence anemia prophylactic darbepoetin alfa support patient treat regimen . - Determine conversion rate complete remission patient treat ibritumomab tiuxetan achieve partial remission post-R-CHOP . - Determine effect darbepoetin alfa quality life patient . OUTLINE : This open-label , nonrandomized study . - Chemotherapy : Patients receive rituximab IV 2-5 hour , cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 ; oral prednisone day 1-5 2-6 ; filgrastim ( G-CSF ) subcutaneously ( SC ) day 7-15 . Patients also receive darbepoetin alfa SC day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Radioimmunotherapy : Patients receive rituximab IV 3-5 hour indium In 111 ibritumomab tiuxetan ( IDEC-In2B8 ) IV 10 minute day 0 . Patients undergo gamma camera image 2-24 hour 48-72 hour injection IDEC-In2B8 observe flow ibritumomab tiuxetan . If flow deem safe , patient receive yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 7 . Quality life assess baseline , course 5 chemotherapy , radioimmunotherapy , 3 month . Patients follow every 3 month 1 year every 6 month 4 year . PROJECTED ACCRUAL : A total 65 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large Bcell lymphoma , include follow subtypes : Centroblastic Immunoblastic Tcell/histiocyterich Lymphomatoid granulomatosis type Anaplastic large Bcell Plasmablastic Mediastinal Intravascular large Bcell lymphoma Previously untreated Highintermediate highrisk disease , define ageadjusted international prognostic index score 2 3 ( 1 point assign ECOG great 1/Karnofsky less 80 % , lactate dehydrogenase great normal , stage III IV ) Lymphomas discordant histology diffuse large Bcell component eligible Must initial diagnostic specimen CD20+ At least Ann Arbor stage II disease No confinement disease involvedfield radiotherapy port ( stage I limit stage II disease ) Bidimensionally measurable disease least 1 lymph node least 2.0 cm 2.0 cm physical examination , CT scan , positronemission tomography Bone marrow cellularity great 15 % No known brain leptomeningeal metastases No primary effusion lymphoma PATIENT CHARACTERISTICS : Age 60 over* NOTE : *Patients 60 65 year age must deem ineligible autologous stem cell transplantation Performance status Karnofsky 50100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 2.0 mg/dL ( except Gilbert 's disease ) Renal Creatinine great 1.5 mg/dL* OR Creatinine clearance great 50 mL/min* NOTE : *Patients meet either criterion renal insufficiency directly relate lymphomatous involvement kidney renal collect system allow Cardiovascular Cardiac ejection fraction least 50 % echocardiogram No acute myocardial infarction within past 3 month No uncontrolled hypertension No New York Heart Association class III IV congestive heart failure No unstable angina pectoris Other Not pregnant nursing Fertile patient must use effective contraception HIV negative B12 folate great low limit normal Transferrin saturation least 15 % Ferritin great 10 Âµg/L At least 6 week since prior RBC donation No active seizure disorder Prior seizure disorder allow free antiseizure medication evidence seizure activity past 5 year No concurrent uncontrolled medical problem would preclude administration chemotherapy radioimmunotherapy No concurrent malignancy treat chemotherapy radiotherapy except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior RBC transfusion No prior biologic therapy No concurrent biologic therapy Chemotherapy No prior chemotherapy ( one course RCHOP allow ) No concurrent standard investigational chemotherapy Endocrine therapy No 7 consecutive day prior steroid ( premedication allow prior intravenous contrast allergy ) No concurrent corticosteroid Radiotherapy No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>